Shape's suite of technology platforms broadly enables RNA targeting, RNA editing, and RNA replacement for patients suffering from certain genetic disorders. The company recently announced a breakthrough in RNA delivery with the discovery of next-generation adeno-associated viruses (AAVs) that are central nervous system- or muscle-specific in nonhuman primates.

On the manufacturing front, Shape said it has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods.

The round of series B funding was co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital.

In addition, Shape announced Min Cui, PhD, founder and managing director at Decheng Capital, will join its board of directors.

Mobilion secures $60M for biologic therapeutic characterization
Mobilion Systems has netted $60 million in a series C financing round.

Prime Medicine launches with gene editing technology
Prime Medicine has launched with $315 million in financing to rapidly advance its prime editing gene editing technology.

Shape Therapeutics unveils advanced AAV capsid discovery platform
Shape Therapeutics has unveiled its adeno-associated virus (AAV) discovery platform, AAVid capsid, and results from its first AAV5 variant library in...

UCB expands gene therapy capabilities
UCB has acquired Belgium-based Handl Therapeutics and formed a new collaboration with Florida-based Lacerta Therapeutics to accelerate the company's gene...

New methods could improve AAV quality for viral vector manufacturing
Developing well-characterized adeno-associated viral vectors (AAVs) is a significant obstacle for the biomanufacturing industry. A group of analytical...